SAN JUAN, Puerto Rico, May 15, 2019 (GLOBE NEWSWIRE) — Veritas Pharma Puerto Rico, Inc., a wholly owned subsidiary of Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas”), is pleased to announce the completion of its clinical trial on its lead cannabis treatment (“CTL-X”) for acute pain. The clinical trial was designed as a randomized, double-blinded, cross-over trial and tested the efficacy of vaporized CTL-X for the treatment of acute pain in healthy adult subjects.
FDI Clinical Research (“FDI”), a San Juan-based clinical research organization, conducted the studied following GMP standards. Veritas’ Medical Director Dr. Scott Alexander and FDI’s CEO Dr. Jose F. Rodriguez Orengo designed and successfully carried out this study to obtain clinical data on the safety and potential efficacy of CTL-X in acute pain
During the next three (3) months, Veritas and FDI will analyze